Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge assisted Active Biotech in licensing deal regarding ANYARA
Mandate

Vinge assisted Active Biotech in licensing deal regarding ANYARA

October 27, 2016

Vinge has assisted Active Biotech AB (publ.) in entering into a development and licensing agreement with NeoTX Therapeutics Ltd (”NeoTX”) regarding Active Biotech’s investigational compound ANYARA. NeoTX will be responsible for the worldwide clinical development and commercialization of the drug for cancer indications.
 
Vinge’s team consisted of Erik Sjöman and Kristoffer Franzkeit.

Related

Vinge has advised Eleda in connection with Eleda Norge AS’s acquisition of Nettpartner Bane AS

 Vinge, together with Advokatfirmaet Thommessen, has advised Eleda in connection with Eleda Norge AS’s acquisition of Nettpartner Bane AS from Å Energi owned Nettpartner AS.
January 19, 2026

Vinge advises KEYTO Group in connection with the acquisition of Smartify

 KEYTO Group continues its growth journey by strengthening its offering in Sweden as Smartify Sverige AB joins KEYTO Group.
January 19, 2026

Vinge has advised Orexo in connection with the divestment of the US rights to Zubsolv

 Vinge has advised Orexo in relation to Swedish law in connection with the divestment of the US rights to Zubsolv to Dexcel Pharma USA.
January 14, 2026